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Metformin and Myocardial Injury in Patients With Diabetes and
ST-Segment Elevation Myocardial Infarction: A Propensity Score
Matched Analysis
Suresh Basnet, MD; Andrzej Kozikowski, PhD; Amgad N. Makaryus, MD; Renee Pekmezaris, PhD; Roman Zeltser, MD;
Meredith Akerman, MS; Martin Lesser, PhD; Gisele Wolf-Klein, MD

Background-—Although animal studies have documented metformin’s cardioprotective effects, the impact in humans remains
elusive. The study objective was to explore the association between metformin and myocardial infarct size in patients with diabetes
presenting with ST-segment elevation myocardial infarction.
Methods and Results-—Data extraction used the National Cardiovascular Data CathPCI Registry in all patients with diabetes aged
>18 years presenting with ST-segment elevation myocardial infarction at 2 academic medical centers from January 2010 to
December 2013. The exposure of interest was ongoing metformin use before the event. Propensity score matching was used for
the metformin and nonmetformin groups on key prognostic variables. All matched pairs had acceptable D scores of <10%,
conﬁrming an efﬁcient matching procedure. The primary outcome was myocardial infarct size, reﬂected by peak serum creatine
kinase–myocardial band, troponin T, and hospital discharge left ventricular ejection fraction. Of all 1726 ST-segment elevation
myocardial infarction cases reviewed, 493 patients had diabetes (28.5%), with 208 metformin users (42.1%) and 285 nonusers.
Matched pairs analysis yielded 137 cases per group. The difference between metformin and nonmetformin groups was 18.1 ng/
mL (95% CI 55.0 to 18.8; P=0.56) for total peak serum creatine kinase–myocardial band and 1.1 ng/mL (95% CI 2.8 to 0.5;
P=0.41) for troponin T. Median discharge left ventricular ejection fraction in both groups was 45, and the difference between
metformin and nonmetformin users was 0.7% (95% CI 2.2 to 3.6; P=0.99).
Conclusions-—No statistically signiﬁcant association of cardioprotection was found between metformin and myocardial infarct size
in patients with diabetes and acute ST-segment elevation myocardial infarction. ( J Am Heart Assoc. 2015;4:e002314 doi:
10.1161/JAHA.115.002314)
Key Words: metformin • myocardial injury • ST-segment elevation myocardial infarction

T

he American Heart Association considers diabetes to be
a “major controllable risk factor for cardiovascular
disease [CVD].”1 In addition to lifestyle changes, pharmaco-
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logical therapeutic options including oral hypoglycemic agents
are being actively investigated to determine their potential
impact on CVD-related death independent of their glucoselowering effects. To date, only metformin has shown promising results.2–6
Metformin is associated with lower mortality, both total and
cardiovascular.7 Metformin seems to reduce myocardial
ischemia–reperfusion injury in animal studies8 and in humans
based on a few preliminary studies9,10; however, there is
controversy regarding the possible cardioprotective effect of
metformin. Few recent studies have speciﬁcally investigated
the relationship between metformin use and myocardial
infarction (MI). In a 2013 retrospective analysis, Zhao et al
found that chronic pretreatment with metformin was associated with the reduction of the no-reﬂow phenomenon in
patients with diabetes mellitus after primary angioplasty for
acute MI.9 In a 2014 retrospective cohort study, Lexis et al
sought to investigate the association between metformin use
and MI size in patients presenting with an acute MI.10 The
researchers found that the use of metformin treatment was an
Journal of the American Heart Association
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Methods
Data Source
A retrospective cohort study of patients with diabetes (types 1
and 2) presenting with STEMI was conducted at 2 large
tertiary academic medical centers in the New York metropolitan area. After institutional review board approval (14-122A),
data were extracted from the American College of Cardiology
National Cardiovascular Data Registry (NCDR) covering the
period from January 1, 2010, through December 31, 2013.
The NCDR was developed in 1997 to capture reliable clinical,
process-of-care, and outcomes data for patients undergoing
coronary angiography and PCI in the United States, enabling
practitioners to explore strategies for improving cardiovascular care.15,16 The registry contains >250 data ﬁelds including
patient medical history, risk factors, demographics, hospital
presentation, initial cardiac status, procedural description,
laboratory results, medication regimens, and in-hospital
outcomes.15 The registry contains 12 million records from
1577 institutions in the United States from 1998 to the
present.15 Prior to propensity score matching (PSM), there
were 208 metformin and 285 nonmetformin patients who met
the eligibility criteria for this study. The ﬁnal sample size after
PSM was 274 participants (137 metformin and 137 nonmetformin patients).

Study Population and Selection Criteria
All patients were aged ≥18 years with known diabetes
(deﬁned by a history of diabetes diagnosed by a physician
or fasting blood glucose >7 mmol/L or 126 mg/dL, regardDOI: 10.1161/JAHA.115.002314

less of duration of disease or need for glucose-lowering
medications) and presented with STEMI or STEMI equivalent
(characterized by the presence of both electrocardiogram
evidence and cardiac biomarker criteria). Data for all patients
in this study were extracted from the NCDR CathPCI Registry
version 4.4. Data on use of metformin, antiplatelet agents,
and statin therapy prior to hospitalization were extracted by
manual review of electronic health records for each patient.

Exposure of Interest
The exposure of interest was metformin use prior to STEMI.
Metformin therapy prior to STEMI was deﬁned as the
documentation of a prescription for metformin at a dose of
≥250 mg per day that was in effect on the day prior to
admission, as obtained from patients’ electronic home
medication reconciliation order sheets.

Variables
Preprocedure cardiac biomarkers were recorded, including
creatine kinase–myocardial band (CKMB) and troponin T
measurements. These laboratory tests were drawn at our
facilities and excluded point-of-care or bedside testing, with
the target value being the last value between arrival and
current procedure prior to PCI. Discharge LVEF (DCLVEF) after
PCI was collected as well as postprocedure CKMB and
troponin T peak values (within the interval of 6 to 24 hours
after PCI with the target value being the highest value
between 6 and 24 hours after the current procedure). Other
variables collected included sex, body mass index, race,
history of smoking, hypertension, dyslipidemia, prior MI, use
of antianginal medications, antiplatelet agents, statin therapy,
family history of coronary artery disease, prior PCI, prior heart
failure, coronary artery bypass grafting, CVD, peripheral
arterial disease, chronic lung disease, left ventricular systolic
dysfunction, time from symptom onset to PCI (in hours),
cardiogenic shock at presentation, and current anterior
infarct.

Propensity Score Matching
Given that this was a retrospective cohort study and not a
randomized trial, it was necessary to achieve comparability of
the metformin (intervention) and nonmetformin (control)
groups with regard to potential confounding variables. This
was accomplished using PSM (Figure).17 The following
variables, chosen from the CathPCI Registry, were used to
compute the propensity score for each patient: sex, race,
smoking history, hypertension, dyslipidemia, prior MI, antianginal medication, antiplatelets, statin, family history of coronary
artery disease, prior PCI, body mass index, time from
Journal of the American Heart Association
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independent predictor of smaller MI size.10 Nevertheless,
Abualsuod et al found in a chart review study that the use of
metformin in patients with diabetes was not associated with
improvements in left ventricular ejection fraction (LVEF)
despite being related to both 30-day and 12-month all-cause
mortality.11 This ﬁnding suggests that metformin may be
beneﬁcial without directly inﬂuencing LVEF. In a prospective
trial of metformin for ST-segment elevation MI (STEMI) in
nondiabetic patients, Lexis et al also failed to show a beneﬁcial
effect of metformin on LVEF after 4-month follow-up.12
Despite the encouraging ﬁndings showing that metformin
use is associated with a lower risk of CVD-related mortality,
only a few studies with human participants have speciﬁcally
investigated the relationship between metformin use and
myocardial infarct size.9–11,13,14 We sought to use propensity
score analysis to investigate the association between metformin use and infarct size prior to percutaneous coronary
intervention (PCI) in patients with diabetes presenting with
STEMI.

Metformin and Myocardial Injury in STEMI
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Figure. Propensity score matching ﬂow diagram. NCDR indicates National Cardiovascular Data Registry; STEMI, ST-segment
elevation myocardial infarction.
DOI: 10.1161/JAHA.115.002314

sample size after creating matched pairs. This is also the case
in most epidemiological studies in which variable-speciﬁc
matching is used.

Table 1. Comparability of the Groups Before Matching

Variable

Nonmetformin
(n=285)

Metformin
(n=208)

P Value

D

Sex (male)

196 (68.8%)

147 (70.7%)

0.651

4.1

Race (white)

132 (46.3%)

88 (42.3%)

0.377

8.1

Smoker

53 (18.6%)

51 (24.5%)

0.111

14.4

Hypertension

246 (86.3%)

174 (83.7%)

0.411

7.4

Dyslipidemia

205 (71.9%)

159 (76.4%)

0.260

10.3

Prior MI

48 (16.8%)

21 (10.1%)

0.033

19.8

Antianginal
medication

152 (53.3%)

90 (43.3%)

0.027

20.2

Antiplatelets

131 (46.0%)

83 (39.9%)

0.180

12.2

Statin

133 (46.7%)

127 (61.1%)

0.002

29.1

Family history of
CAD

29 (10.2%)

23 (11.1%)

0.752

2.9

Prior PCI

58 (20.4%)

37 (17.8%)

0.465

6.7

BMI*

29.36.0
[median
28.4 (25.1,
32.6)]

30.37.5
[median
28.3 (25.8,
32.4)]

0.424

14.2

Time from
symptom onset
to PCI, hours*

9.614.1
[median 4.1
(2.6, 10.2)]

8.112.4
[median
3.8 (2.3,
7.9)]

0.231

11.1

Anterior infarct

99 (35.1%)

60 (30.3%)

0.271

10.2

Combined
predictor
variable†

93 (32.6%)

33 (15.9%)

<0.0001

39.8

Prior HF

29 (10.2%)

9 (4.3%)

0.016

—

Prior CABG

19 (6.7%)

6 (2.9%)

0.059

—

Prior CVD

20 (7.0%)

11 (5.3%)

0.435

—

Prior PAD

21 (7.4%)

7 (3.4%)

0.059

—

Chronic lung
disease

12 (4.2%)

5 (2.4%)

0.278

—

Cardio LVSD

14 (4.9%)

6 (2.9%)

0.260

—

Cardiogenic
shock

16 (5.6%)

1 (0.5%)

0.002

—

BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CVD, cardiovascular disease; HF, heart failure; LVSD, left ventricular
systolic dysfunction; MI, myocardial infarction; PAD, peripheral arterial disease; PCI,
percutaneous coronary intervention.
*All categorical data are reported as frequency (percentage). The 2 continuous variables,
BMI and time from symptom onset to PCI, are reported as meanSD and median (25th,
75th percentiles).
†
Only the combined predictor variable was used in propensity score matching. The 7
components of this variable are shown for informational purposes only.
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symptom onset to PCI (in hours), and anterior infarct. In
addition, a composite predictor variable was used that
indicated the presence of at least 1 of the following
conditions: prior heart failure, coronary artery bypass grafting,
prior CVD, prior peripheral arterial disease, chronic lung
disease, left ventricular systolic dysfunction, and cardiogenic
shock. PSM was accomplished using the SAS macro
OneToManyMTCH.18
The standardized difference statistic (D, expressed as a
percentage) was used to evaluate comparability of the 2
groups on each confounding variable before and after PSM.19
Comparability of the 2 groups with respect to the potential
confounders before matching (n=208 metformin, n=285
controls) and after matching (n=137 metformin, n=137
controls) was also evaluated using descriptive statistics; the
2-sample t test for continuous variables; and the chi-square
test or Fisher exact test, as deemed appropriate, for
categorical variables. Summary statistics before matching
(Table 1) and after matching (Table 2) were reported as
frequency (percentage) for categorical data and as mean and
SD and median (25th, 75th percentiles) for continuous data.
It should be noted that it is common for the sample size
prior to PSM to be quite large compared with the resulting
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Variable

Nonmetformin
(n=137)

Metformin
(n=137)

P Value

D

Sex (male)

87 (63.5%)

89 (65.0%)

0.801

3

Race (white)

62 (45.3%)

64 (46.7%)

0.808

2.9

Smoker

27 (19.7%)

30 (21.9%)

0.655

5.4

Hypertension

117 (85.4%)

112 (81.8%)

0.415

9.8

Dyslipidemia

102 (74.5%)

97 (70.8%)

0.498

8.2

Prior MI

22 (16.1%)

18 (13.1%)

0.494

8.2

Antianginal
medication

61 (44.5%)

62 (45.3%)

0.903

1.5

Antiplatelets

62 (45.3%)

62 (45.3%)

1.000

0

Statin

71 (51.8%)

71 (51.8%)

1.000

0

Family history of CAD

12 (8.8%)

15 (11.0%)

0.543

7.3

Prior PCI

28 (20.4%)

30 (21.9%)

0.767

3.6

BMI*

30.46.4
[median
29.2 (25.8,
33.3)]

30.27.1
[median
28.2 (25.8,
32.4)]

0.407

2.9

Time from symptom
onset to PCI, hours*

1.61.1
[median 1.4
(0.9, 2.3)]

1.51.0
[median
1.4 (0.8,
2.1)]

0.570

2.2

Anterior infarct

48 (35.0%)

44 (32.1%)

0.609

6.2

Combined predictor
variable†

20 (14.6%)

20 (14.6%)

1.000

0

4 (2.9%)

7 (5.1%)

0.356

Prior HF

4 (2.9%)

2 (1.5%)

0.684

Prior CVD

2 (1.5%)

9 (6.6%)

0.031

3 (2.2%)

4 (2.9%)

1.000

—
‡

—
—

‡

—

‡

—

Chronic lung
disease

5 (3.7%)

4 (2.9%)

1.000

Cardio LVSD

4 (2.9%)

5 (3.7%)

1.000‡

—

‡

—

Cardiogenic shock

4 (2.9%)

0 (0.0%)

0.122

BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CVD, cardiovascular disease; HF, heart failure; LVSD, left ventricular
systolic dysfunction; MI, myocardial infarction; PAD, peripheral arterial disease; PCI,
percutaneous coronary intervention.
*All categorical data are reported as frequency (percentage). The 2 continuous variables,
BMI and time from symptom onset to PCI, are reported as meanSD and median (25th,
75th percentiles).
†
Only the combined predictor variable was used in propensity score matching. The 7
components of this variable are shown for informational purposes only.
‡
Fisher exact test.

Primary Outcome
The primary study outcome variable was myocardial infarct
size as demonstrated by the peak levels of cardiac biomarkers
and DCLVEF after the STEMI event. In cases in which CKMB
(and similarly for troponin T) was measured both before and

DOI: 10.1161/JAHA.115.002314

Statistical Analyses
Comparisons of the metformin and control groups were
carried out using methods for paired continuous data. For
CKMB and troponin T, the difference between metformin and
control was calculated as the arithmetic difference (metformin
minus control). The paired arithmetic difference was normally
distributed and was analyzed using the paired t test and
associated 95% CIs.
Conﬁdence intervals for the metformin-minus-control
arithmetic difference are presented in the usual way (Table 3).
A result was considered statistically signiﬁcant at the P<0.05
level. All analyses were performed using SAS version 9.3 (SAS
Institute Inc).

Results

Prior CABG

Prior PAD

after the PCI, the larger of the 2 measurements was used to
capture the worst possible cardiac tissue injury. Peak levels of
cardiac biomarkers (CKMB and troponin T) and LVEF after
acute MI have been shown to have a strong correlation with
myocardial infarct size and scar tissue in humans.20,21

Of the 15 individual and composite predictor confounding
variables, 10 had poor standardized difference scores (ie,
>10%) prior to PSM. After PSM, there were 137 pairs of
metformin and control patients. All 15 confounding variables
had acceptable D scores (ie, <10%), indicating that the
matching procedure was efﬁcient in creating balance between
the 2 groups. Tables 1 and 2 show the comparability statistics
before and after PSM, respectively, for each of the potential
confounding variables.
Although the analysis based on PSM is the focus of this
study, it may be of interest to note that a direct, unadjusted,
unmatched comparison of the 208 metformin patients and
285 controls resulted in no signiﬁcant differences with
respect to CKMB, troponin T, or DCLVEF.
Of all 1726 STEMI cases reviewed, 493 patients had
diabetes (28.5%), with 208 (42.1%) metformin users and 285
nonusers. Matched pairs analysis yielded 137 cases per
group. The arithmetic difference between the metformin and
nonmetformin groups was 18.1 ng/mL (95% CI 55.0 to
18.8; P=0.56) for total peak serum CKMB and 1.1 ng/mL
(95% CI 2.8 to 0.5; P=0.41) for troponin T. Median DCLVEF
in both groups was 45. The arithmetic difference of DCLVEF
between metformin and nonmetformin users was 0.7% (95%
CI 2.2 to 3.6; P=0.98).The matched pairs comparison of the
137 metformin and control patients showed no signiﬁcant
differences with respect to CKMB, troponin T, or DCLVEF
(Table 3), with P values ranging from 0.410 to 0.987. The
conﬁdence interval for DCLVEF is narrow, allowing the
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Table 3. Matched Pairs Analyses of Primary Outcome Variables
Metformin

Nonmetformin

Difference* and 95% CI for Difference

CKMB (n=136 pairs)

149.6129.0 (median 99.0)

167.6180.7 (median 92.6)

18.1 ( 55.0 to 18.8)

0.561

Troponin T (n=135 pairs)

5.74.9 (median 3.9)

6.89.4 (median 4.1)

1.1 ( 2.8 to 0.5)

0.410

DCLVEF (n=127 pairs)

43.511.1 (median 45.0)

42.811.6 (median 45.0)

0.7 ( 2.2 to 3.6)

P Value

0.987

Data were analyzed using the paired t test. CKMB indicates creatine kinase–myocardial band; DCLVEF, discharge left ventricular ejection fraction.
*A positive (negative) difference indicates a larger (smaller) value for the metformin group.

conclusion that there is no appreciable difference in this
outcome between the 2 groups.

Discussion
The major objective of our study was to investigate the
association between metformin use prior to PCI and myocardial injury in patients with diabetes and STEMI. In our
propensity score matched study, the results showed no
signiﬁcant differences with respect to CKMB, troponin T, and
DCLVEF.
Numerous studies have shown that metformin is associated with a lower risk for CVD-related complications and
death.7,13,22–25 In 1998, a study on the effects of intensive
blood glucose control with metformin on macrovascular and
microvascular complications and mortality in overweight
patients with diabetes found that those receiving metformin
had risk reduction of 36% for all-cause mortality and 46% for
diabetes-related death.7 Similarly, in 2002, Johnson et al
documented that metformin therapy was associated with
lower all-cause and cardiovascular mortality compared with
sulfonylurea monotherapy.22 In a 2008 systematic review,
based on 40 controlled trials, Selvin et al found that
metformin treatment was associated with a lower cardiovascular mortality risk compared with other oral glucose-lowering
medications or a placebo.23
In a post hoc analysis from the Diabetes Mellitus Insulin–
Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2
trial, Melbin et al found that metformin was associated with a
lower mortality rate.13 In 2011, a nationwide Danish study
explored the relationship between mortality and cardiovascular risk associated with different insulin secretagogues
compared with metformin in patients with type 2 diabetes
with or without a previous MI.24 Monotherapy with metformin
resulted in decreased mortality risk compared with glimepiride, glibenclamide, glipizide, and tolbutamide. In a randomized
double-blind placebo-controlled trial investigating the effect of
metformin compared with glipizide on cardiovascular outcomes in patients with type 2 diabetes and CVD, metformin
treatment led to a signiﬁcantly lower number of major
cardiovascular events compared with glipizide at 5 years (7

DOI: 10.1161/JAHA.115.002314

versus 14 deaths, respectively).25 The GLP-1 receptor agonist
exenatide has been demonstrated to be cardioprotective in
both animal studies26 and clinical trials.27–29 Conversely,
sulphonylurea antidiabetic drugs seem to disrupt cardioprotection through inhibition of ATP-dependent potassium channels.30
Animal studies suggest that metformin induces cardioprotection against ischemia and reperfusion injury, independently
from its glucose-lowering effect, by limiting myocardial infarct
size and remodeling.8,31–33 In a 2008 study conducted in rats,
a single metformin dose protected the myocardium against
experimentally induced ischemia 24 hours after administration of the drug, with an acute increase in myocardial
adenosine monophosphate–activated protein kinase activity
and a signiﬁcant reduction of myocardial infarct size.31 More
recently, in a 2013 study, chronic metformin administration
once again resulted in cardioprotection against infarction in
the form of myocardial resistance to ischemia–reperfusion
injury in diabetic and nondiabetic rats.32 This research
suggests that metformin positively affects mitochondrial
structure through adenosine monophosphate–activated protein kinase activation and proliferator-activated receptor-c
coactivator (PGC-1a) by restricting the occurrence of myocardial injury from cardiovascular events.
In humans, a recent retrospective cohort study sought to
investigate the association between metformin use and MI
size in patients presenting with an acute MI.10 The
researchers divided patients with diabetes into metformin
versus nonmetformin groups and estimated MI size using
peak values of serum creatine kinase, CKMB, and troponin
T.10 After adjustment for age, sex, Thrombolysis in Myocardial
Infarction ﬂow after PCI, and previous MI, Lexis et al found
that the use of metformin treatment remained an independent
predictor of smaller MI size10; however, in a double-blind,
placebo-controlled study in nondiabetic participants, also
conducted by Lexis et al, the use of metformin compared with
placebo did not result in improved LVEF after 4 months.12 The
negative outcome results shown by Lexis et al in their trial
could have been due to the study procedure, which involved
providing patients with metformin after the event of STEMI
and PCI.
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who usually are insulin dependent. A last limitation of our
study is that we could use data from only 2 of our institutions.
NCDR compiles data from 1577 participating institutions but
provides access to raw data for research only to the
institution from which the data originated. Data from other
institutions are provided in the form of national risk-adjusted
benchmark reports. In addition, NCDR does not provide data
on use of metformin; in our study, this was extracted from
manual review of individual patients’ electronic medical
records.
Although studies have previously documented beneﬁcial
cardioprotective effects of metformin, the exact mechanism
and presence of this effect in humans remains elusive. It
appears that infarct size in the setting of myocardial injury is
not associated with metformin use in the present era of
primary PCI. Further prospective controlled trials may help
elucidate the effect of metformin with respect to cardioprotection and allow for the enhanced care of patients experiencing an acute coronary event.

Disclosures
None.
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patients with diabetes on metformin therapy prior to the
event. We used PSM to control for 15 potential confounding/
composite variables including sex, race, smoking history,
hypertension, dyslipidemia, prior MI, antianginal medication,
antiplatelets, statin, family history of coronary artery disease,
prior PCI, body mass index, time from symptom onset to PCI,
anterior infarct, and a combined predictor variable (prior heart
failure, coronary artery bypass grafting, CVD, peripheral
arterial disease, chronic lung disease, cardiovascular left
ventricular systolic dysfunction, and cardiogenic shock).
The “negative” results in our study need to be interpreted
in the context of whether these might be type II errors. A way
to address this is by examining the associated conﬁdence
intervals as follows: Given the narrow conﬁdence interval for
DCLVEF (95% CI 2.2 to 3.6; P=0.987) and even at the
extremes of this conﬁdence interval, there appears to be no
clinically signiﬁcant difference, which allows us to conclude
that there is no appreciable difference in DCLVEF between the
metformin and nonmetformin groups. The same can be said of
troponin T because its conﬁdence interval (95% CI 2.8 to
0.5; P=0.41) also suggests that, at the extremes, there is no
clinically appreciable difference.
With regard to difference in CKMB, the wider conﬁdence
interval and the lower and upper end points (95% CI 55.0 to
18.8) suggest that group differences could be clinically
meaningful. Consequently, the observed lack of group difference for CKMB may be inconclusive (ie, type II error).
The main limitation of this study is that it takes into
account only ﬁnal infarct size, not the myocardial salvage
area. We found that the infarct size was similar in both
groups, but there are 2 confounding factors with this result:
variations in coronary anatomy and the possibility that
coronary occlusions were more proximal in 1 group than in
the other group, so the area at risk (the ischemic area) was
larger, and that justiﬁes a larger infarct size. We cannot rule
out that metformin was cardioprotective, but the metformin
group had a larger ischemic area from the very beginning.
Another limitation of our study is that we did not collect data
on the duration of metformin use, the speciﬁc doses, or
patients’ adherence to their medication regimens. If patients
started metformin the previous day, they would still be
achieving plasma steady-state levels; however, not knowing
the speciﬁc dose (metformin may be cardioprotective at
speciﬁc doses) and whether they were noncompliant with the
treatment limits our study results. An additional limitation is
that we could not differentiate between patients with type 1
and 2 diabetes in our sample because the CathPCI Registry
groups all patients with diabetes into 1 category; however,
metformin is the ﬁrst-line drug for type 2 diabetes and
typically is not prescribed to patients with type 1 diabetes,

Metformin and Myocardial Injury in STEMI

Basnet et al

23. Selvin E, Bolen S, Yeh H-C, Wiley C, Wilson LM, Marinopoulos SS, Feldman L,
Vassy J, Wilson R, Bass EB. Cardiovascular outcomes in trials of oral diabetes
medications: a systematic review. Arch Intern Med. 2008;168:2070–2080.

12. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel
AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES. Effect of metformin on
left ventricular function after acute myocardial infarction in patients without
diabetes: the GIPS-III randomized clinical trial. J Am Med Assoc. 2014;311:
1526–1535.

24. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl
EL, Køber L, Norgaard ML, Madsen M. Mortality and cardiovascular risk
associated with different insulin secretagogues compared with metformin in
type 2 diabetes, with or without a previous myocardial infarction: a nationwide
study. Eur Heart J. 2011;32:1900–1908.

13. Mellbin L, Malmberg K, Norhammar AF, Wedel H, Ryden L; Investigators D.
Prognostic implications of glucose-lowering treatment in patients with acute
myocardial infarction and diabetes: experiences from an extended follow-up of
the diabetes mellitus insulin–glucose infusion in acute myocardial infarction
(DIGAMI) 2 study. Diabetologia. 2011;54:1308–1317.

25. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L.
Effects of metformin versus glipizide on cardiovascular outcomes in patients
with type 2 diabetes and coronary artery disease. Diabetes Care.
2013;36:1304–1311.

14. Paneni F, Costantino S, Cosentino F. Metformin and left ventricular remodeling
after acute myocardial infarction: molecular mechanisms and clinical implications. G Ital Cardiol (Rome). 2015;16:225–231.

26. Timmers L, Henriques JP, de Kleijn DP, DeVries JH, Kemperman H, Steendijk P,
Verlaan CW, Kerver M, Piek JJ, Doevendans PA. Exenatide reduces infarct size
and improves cardiac function in a porcine model of ischemia and reperfusion
injury. J Am Coll Cardiol. 2009;53:501–510.

15. Moussa I, Hermann A, Messenger JC, Dehmer GJ, Weaver WD, Rumsfeld JS,
Masoudi FA. The NCDR CathPCI Registry: a US national perspective on care
and outcomes for percutaneous coronary intervention. Heart. 2013;99:297–
303. doi: 10.1136/heartjnl-2012-303379.

27. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB,
Jørgensen E, Helqvist S, Saunam€aki K, Clemmensen P. Exenatide reduces
reperfusion injury in patients with ST-segment elevation myocardial infarction.
Eur Heart J. 2012;33:1491–1499.

16. National Cardiovascular Data Registry. CathPCI Registry for diagnostic cardiac
catheterizations and percutanious coronary interventions. Available at:
https://www.ncdr.com/webncdr/cathpci/. Accessed October 3, 2014.

28. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen
E, Helqvist S, Saunam€aki K, Terkelsen CJ. Exenatide reduces ﬁnal infarct size in
patients with ST-segment–elevation myocardial infarction and short-duration
of ischemia. Circulation. 2012;5:288–295.

17. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using
subclassiﬁcation on the propensity score. J Am Stat Assoc. 1984;79:516–524.
18. Parsons LS. Performing a 1:N case-control match on propensity score.
Proceedings of the 29th Annual SAS Users Group International Conference.
May 9–12, 2004. Montreal, Canada.
19. Austin PC. Assessing balance in measured baseline covariates when using
many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf.
2008;17:1218–1225.

29. Woo JS, Kim W, Ha SJ, Kim JB, Kim S-J, Kim W-S, Seon HJ, Kim KS.
Cardioprotective effects of exenatide in patients with ST-segment–elevation
myocardial infarction undergoing primary percutaneous coronary intervention
results of exenatide myocardial protection in revascularization study.
Arterioscler Thromb Vasc Biol. 2013;33:2252–2260.
30. Meier J, Gallwitz B, Schmidt W, M€ugge A, Nauck M. Is impairment of ischaemic
preconditioning by sulfonylurea drugs clinically important? Heart. 2004;90:9–12.

20. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium
delayed enhancement cardiovascular magnetic resonance correlates with
clinical measures of myocardial infarction. J Am Coll Cardiol. 2004;43:2253–
2259.

31. Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Bøtker HE,
Schmitz O, Lund S. Metformin induces cardioprotection against ischaemia/
reperfusion injury in the rat heart 24 hours after administration. Basic Clin
Pharmacol Toxicol. 2008;103:82–87.

21. Chia S, Senatore F, Raffel OC, Lee H, Frans JT, Jang I-K. Utility of cardiac
biomarkers in predicting infarct size, left ventricular function, and clinical
outcome after primary percutaneous coronary intervention for ST-segment
elevation myocardial infarction. J Am Coll Cardiol. 2008;1:415–423.

32. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu
MM. Chronic metformin associated cardioprotection against infarction: not
just a glucose lowering phenomenon. Cardiovasc Drugs Ther. 2013;27:5–16.

22. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality
associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–2248.

DOI: 10.1161/JAHA.115.002314

33. Paiva MA, Rutter-Locher Z, Goncßalves LM, Provid^encia LA, Davidson SM,
Yellon DM, Mocanu MM. Enhancing AMPK activation during ischemia protects
the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol.
2011;300:H2123–H2134.

Journal of the American Heart Association

7

ORIGINAL RESEARCH

11. Abualsuod A, Rutland JJ, Watts TE, Pandat S, Delongchamp R, Mehta JL. The
effect of metformin use on left ventricular ejection fraction and mortality postmyocardial infarction. Cardiovasc Drugs Ther. 2015;29:265–275.

